A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Leptomeningeal Disease|Triple Negative Breast Cancer|HER2-positive Breast Cancer
Interventions: BIOLOGICAL: Dendritic Cell Vaccine
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: United States Department of Defense